The pathophysiologic mechanisms of Guillain-Barré syndrome (GBS) associated with Zika virus (ZIKV) infection may be indicated by differences in clinical features.
G uillain-Barré syndrome (GBS) is an uncommon autoimmune condition, characterized by progressive, bilateral weakness and diminished reflexes. 1 It has been associated with infectious agents, including Campylobacter jejuni, 2 and (less frequently) with vaccines. 1 The global annual GBS incidence is estimated at 1.1 to 1.8 cases per 100 000 population, increasing with age and varying by sex and geographic region. 3 Mortality rates among patients with GBS in North America and Europe varyfrom3%to7%, 1 with death most often resulting from respiratory failure, autonomic dysfunction, or deep vein thrombosis. 4 In Puerto Rico, the annual GBS incidence before the introduction of Zika virus (ZIKV) was estimated at 1.7 cases per 100 000 population, and in-hospital mortality was estimated at 4%. 5 Increased GBS incidence during ZIKV epidemics has provided a unique opportunity to further delineate the clinical features and pathophysiology of GBS. [6] [7] [8] [9] [10] [11] The Puerto Rico Department of Health (PRDH), in San Juan, reported the first case of ZIKV disease in December 2015. Staff at the Adult's University Hospital (San Juan) suspected antecedent ZIKV infection in a patient with GBS who was seen in January 2016; specimen testing by the PRDH and the US Centers for Disease Control and Prevention (CDC), San Juan, Puerto Rico, detected evidence of ZIKV infection. 12 Thereafter, emergency public health surveillance was implemented to prospectively identify GBS cases and test patient specimens for evidence of infection with ZIKV, dengue virus (DENV), and chikungunya virus (CHIKV). 13, 14 To characterize GBS associated with ZIKV infection and lend insights into pathophysiologic mechanisms, we analyzed the clinical features of patients with GBS in Puerto Rico with vs without evidence of ZIKV infection who had neurologic illness onset during 2016.
Methods

GBS Case Identification
This investigation was reviewed by the CDC human participants' research advisors and was determined to be nonresearch emergency public health activities; patient informed consent was not required to report suspected cases. In February 2016, a passive GBS surveillance system was implemented to prospectively identify GBS cases in Puerto Rico 13, 14 ; in October 2016, reporting of suspected and fatal GBS cases was made compulsory. 15 Health care professionals were requested to report suspected GBS cases using a case report form along with serum specimens (eFigure 1 in the Supplement); if available, urine, cerebrospinal fluid (CSF), and saliva specimens were also submitted. During February through April 2017, all 57 nonspecialized hospitals and 2 rehabilitative inpatient care centers in Puerto Rico provided lists of patients hospitalized during 2016 who had an International Statistical Classification of Health Related Problems and Diseases, Tenth Revision, diagnostic code for GBS (code G61.0) in their medical record.
Arbovirus Diagnostic Testing
Patient specimens were tested using a real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) Trioplex assay to detect evidence of current infection with ZIKV, DENV, and CHIKV. 16 Serum and CSF specimens were also tested by IgM enzyme-linked immunosorbent assay (ELISA) to detect anti-ZIKV, anti-DENV, and anti-CHIKV IgM antibodies. [17] [18] [19] Cases with evidence of ZIKV infection were positive for ZIKV by rRT-PCR and/or IgM ELISA. Cases without evidence of ZIKV infection were negative or equivocal for ZIKV in all specimens by both rRT-PCR and IgM ELISA. Only results from specimens collected within 2 months before neurologic illness onset or during hospitalization for neurologic illness were considered. The database for the Puerto Rico Passive Arboviral Disease Surveillance System was queried for laboratory test results.
Confirmation of GBS Diagnosis and Clinical Data Collection
Medical record review was conducted to confirm GBS diagnosis for all suspected GBS cases reported via passive surveillance and cases retrospectively identified by diagnostic code that had hospital stays of at least 3 days and no alternative diagnosis of neurologic illness. Guillain-Barré syndrome diagnosis was confirmed using the Brighton Collaboration criteria, 20 which include data on clinical presentation, CSF laboratory results, and electrophysiologic findings. Confirmed GBS cases met the Brighton Collaboration criteria levels 1 through 3 or criteria for Miller-Fisher syndrome phenotype. 20 Cases that did not meet these criteria and had no alternative final diagnosis were considered suspected GBS cases. Medical record reviews were performed after hospital discharge or more than 28 days after neurologic illness onset. Collected data included demographic characteristics, place of residence, acute antecedent illness, inhospital infectious disease testing, clinical course of neurologic illness, medical interventions, electrodiagnostic study and imaging results, and hospital discharge status. Cytoalbuminologic dissociation was defined as a total CSF white blood cell count less than 50 cells/μL and a CSF protein concentration of at least 45 mg/dL. Modified Rankin Scale score and Hughes Disability Score were calculated for disability at clinical nadir.
21,22
Assessment of Long-term Disability
Long-term disability data approximately 6 months after neurologic illness onset were collected through telephone interview. Oral informed consent was obtained before interview. Patients were considered lost to follow-up after 5 telephone calls at different times of the day without establishing contact. The administered questionnaire used the modified Rankin Scale, Overall Disability Sum Score, 23 and Facial Disability Index. 24 Self-reported data on substantial fatigue and pain at the time of interview and poor mental status within the past 30 days were also collected.
Statistical Analysis
Frequencies were calculated for demographic, laboratory, clinical, and long-term disability data. Rico and by public health region. 25 Population data were stratified by persons 50 years or older vs persons younger than 50 years.
Results
Case Identification, Arbovirus Diagnostic Test Findings, and Epidemiologic Characteristics
Health care professionals reported a total of 135 suspected GBS cases with neurologic illness onset in 2016, of which 98 (72.6%) were confirmed GBS cases, 8 (5.9%) were suspected GBS cases, and 29 (21.5%) were noncases (eFigure 2 in the Supplement).
A total of 181 individual patients were identified by diagnostic code, of whom 100 (55.2%) had been reported through passive surveillance. Nine of 181 (5.0%) were excluded from additional evaluation given hospital stays less than 3 days (n = 3) and discharge diagnosis (n = 9). After medical record review of the remaining 72 previously unreported patients, 25 (34.7%) were confirmed GBS cases, 4 (5.6%) were suspected GBS cases, and 43 (59.7%) were noncases. Combined, 123 confirmed GBS cases were identified. Their median age was 54 years (age range, 4-88 years), and 68 patients (55.3%) were male. A total of 107 confirmed GBS cases (87.0%) had at least one specimen submitted for arbovirus Among the 71 confirmed GBS cases with evidence of ZIKV infection, a total of 107 serum specimens, 43 urine specimens, 32 CSF specimens, and 18 saliva specimens were submitted and had available ZIKV rRT-PCR and/or IgM ELISA test results ( Figure 1 and eTable 2 in the Supplement). For specimens collected during days 0 through 9 after neurologic illness onset, ZIKV nucleic acid was detected by rRT-PCR in 17 (26.2%) of 65 serum specimens, 5 (18.5%) of 27 urine specimens, and 1 (5.0%) of 20 CSF specimens. For specimens collected at least 10 days after neurologic illness onset, ZIKV nucleic acid was detected by rRT-PCR in 5 of 26 (19.2%) serum specimens and 1 of 16 (6.3%) urine specimens but in none of 11 CSF specimens. Zika virus nucleic acid was not detected in any saliva specimens. Of specimens with ELISA results, anti-ZIKV IgM antibodies were detected in 90 of 95 (94.7%) serum specimens and 9 of 31 (29.0%) CSF specimens (Figure 1 ).
Compared with confirmed GBS cases without evidence of ZIKV infection, those with evidence of ZIKV infection did not differ by age but were more frequently female ( Table 1) . The monthly GBS case count by date of neurologic illness onset increased during the first half of the year, peaked in August, and decreased thereafter, mirroring identified ZIKV disease cases ( Figure 2) . The incidence of GBS in 2016 was 2.1-fold higher than the estimated annual baseline incidence (3.5 vs 1.7 cases per 100 000 population), and the incidence in August was 4.8-fold greater than the estimated baseline. Confirmed GBS cases were identified in all 8 public health regions (Figure 3) . The San Juan metropolitan area had the highest proportion of cases and annual incidence (5.0 cases per 100 000 population) ( Figure 3C ). The incidence of confirmed GBS cases was higher among individuals 50 years or older than among individuals younger than 50 years (6.4 vs 2.1 cases per 100 000 population; P < .001).
Acute Clinical Characteristics of Patients With GBS and Evidence of ZIKV Infection
Although patients with GBS with vs without evidence of ZIKV infection did not differ by frequency of reported antecedent illness, those with evidence of ZIKV infection more frequently reported antecedent rash and arthralgia (Table 1) . Patients with vs without evidence of ZIKV infection did not differ by the median time from antecedent illness to neurologic illness onset.
All patients with confirmed GBS were hospitalized, with no difference between those with vs without evidence of ZIKV infection by duration of hospitalization, certain medical complications, or proportion that received intravenous immunoglobulin (Table 1) . Patients with evidence of ZIKV infection more frequently were admitted to the intensive care unit and required mechanical ventilation. In-hospital deaths did not differ between patients with vs without evidence of ZIKV. Compared with patients with GBS without evidence of ZIKV infection, those with evidence of ZIKV infection more frequently had facial weakness, dysphagia, shortness of breath, and facial paresthesia ( Table 1) . Frequency of other signs and symptoms of neurologic illness did not differ between patients with vs without evidence of ZIKV infection. Among 84 patients with GBS for whom CSF was analyzed, patients with evidence of ZIKV infection more frequently had abnormally elevated protein levels and cytoalbuminologic dissociation; there was no difference in terms of the time between neurologic symptom onset and lumbar puncture. Of 19 patients with and 14 patients without evidence of ZIKV infection who had electrophysiologic studies performed and results available, the overall difference by result was not significant; however, a larger proportion of patients with evidence of ZIKV infection had the acute inflammatory demyelinating polyneuropathy (AIDP) variant of GBS. At clinical nadir, the median modified Rankin Scale score and Hughes Disability Score did not differ between patients with vs without evidence of ZIKV infection.
Long-term Disability of Patients With GBS and Evidence of ZIKV Infection
Data on disability 6 months after onset of neurologic illness were available for 60 patients (84.5%) with and 27 patients (75.0%) without evidence of ZIKV infection ( Table 2 ). The median disability scores did not differ between patients with vs without evidence of ZIKV infection. However, patients with evidence of ZIKV infection more frequently reported ongoing facial disability, including excessive or inadequate tearing and difficulty drinking from a cup. Patients with evidence of ZIKV infection also more frequently reported substantial pain at the time of interview but not substantial fatigue or poor mental status. An additional 7 deaths were identified through follow-up interviews, 3 of which were patients with evidence of ZIKV infection.
Discussion
Prospective and retrospective case identification of patients with GBS with and without evidence of ZIKV infection allowed for the clinical characterization of GBS associated with ZIKV. As reported elsewhere, 6,7,26 the GBS incidence increased above the estimated baseline concurrent to the 2016 ZIKV epidemic in Puerto Rico; however, the increased incidence was lower than the estimated increase of 3.2 to 5.1 times the baseline. 27 Early reports from countries affected by ZIKV facilitated rapid implementation of rigorous laboratory-based case definitions for evidence of ZIKV infection and standardized GBS case definitions, which likely contributed to more accurate epidemiologic data. Concordant with GBS epidemiology, the GBS incidence was higher among those 50 years or older. Unexpectedly, patients with GBS and evidence of ZIKV infection were more frequently female, mirroring the higher incidence of ZIKV disease among this sex in Puerto Rico and elsewhere. [28] [29] [30] [31] Timing of specimen collection was important in detecting ZIKV nucleic acid by rRT-PCR among 39.4% (28 of 71) of patients with GBS and evidence of ZIKV infection. Most specimens with confirmatory results were collected within 9 days of neurologic illness onset. Compared with urine specimens, a higher proportion of serum specimens had positive ZIKV rRT-PCR results, with the added benefit of also being able to detect anti-ZIKV antibodies. Results are consistent with those reported from Brazil 32 and further suggest that ZIKV RNA persistence was similar among patients with ZIKV disease and those who developed GBS after ZIKV infection. For patients with GBS, adding the median times from antecedent illness to neurologic illness onset (7 days) and from neurologic illness onset to specimen collection (9 days), the time from antecedent illness to specimen collection was roughly 16 days. This is comparable to patients with ZIKV disease, in whom ZIKV RNA is detectable in serum specimens for a median of 14 days after onset of ZIKV disease. 33 With regard to antecedent illness, patients with GBS and evidence of ZIKV infection more frequently reported rash and arthralgia but did not differ in terms of the median time from antecedent illness to neurologic illness onset (7 days). The median time to neurologic illness onset for patients with GBS and evidence of ZIKV infection was similar to what has been reported elsewhere. 6, 7 Furthermore, before the introduction of ZIKV, patients with GBS in Puerto Rico also had a median time to neurologic illness onset of 7 days. 5 Therefore, the median time to neurologic illness onset was similar for patients with GBS associated with ZIKV and those triggered by other etiologies. Although all identified patients with GBS were hospitalized, patients with evidence of ZIKV infection had more severe morbidity (ie, more frequently were admitted to the intensive care unit and required mechanical ventilation) and differential longterm outcomes (ie, higher frequency of excessive or inadequate tearing, difficulty drinking from a cup, and self-reported substantial pain). Nonetheless, disability scores at clinical nadir, medical complications, and long-term disability scores did not differ between patients with vs without evidence of ZIKV infection; in-hospital mortality rates also did not differ and were within the expected range for Puerto Rico. 5 Therefore, although acute morbidity may be more severe for patients with GBS and evidence of ZIKV infection, mortality and patient prognosis are similar to GBS associated with other etiologies. This investigation also lends insights into pathophysiologic mechanisms of GBS triggered by ZIKV. Most ZIKV infections are asymptomatic 31, 34 ; however, inversely, 80.3% (57 of 71) of patients herein with GBS and evidence of ZIKV infection reported an antecedent illness. Furthermore, patients with GBS and evidence of ZIKV more frequently had abnormally elevated levels of protein in CSF and cytoalbuminologic dissociation, indicating a heightened immune response compared with GBS triggered by other etiologies. Future research should investigate risk factors for developing GBS after ZIKV infection, as well as for developing GBS triggered by ZIKV compared with other etiologies. The AIDP variant of GBS was predominant among patients with evidence of ZIKV infection, as indicated by electrophysiologic results elsewhere 10 and by phenotypic evidence from a postmortem investigation of a Puerto Rico patient with GBS and evidence of ZIKV infection. 11 Specific mechanisms leading to anti-ZIKV antibodymediated demyelination should be investigated, particularly to identify specific target antigens. 35 Finally, although clinically similar to patients with GBS but without evidence of ZIKV infection, those with evidence of ZIKV infection more frequently had acute and residual cranial neuropathy. This suggests that the immune response to ZIKV infection may more regularly target cranial nerves compared with GBS triggered by other etiologies. 7, 9, 11, 36, 37 Research should examine anti-ZIKV antibody targets, such as antigens that are specific to or overexpressed in cranial nerves.
Limitations
These findings are subject to several limitations. First, patients with GBS may have been missed, including patients who did not seek medical attention, mild and fatal cases without clinical suspicion of GBS, and suspected GBS cases without sufficient documented clinical evidence to meet the Brighton Collaboration criteria. However, a separate analysis of GBS case identification completeness found that an estimated 97% of all confirmed GBS cases with neurologic illness onset during 2016 were identified. 14 Second, ZIKV infection among patients with GBS could have been misclassified. Cross-reactivity with DENV by IgM ELISA could have led to an overestimation of patients having GBS with evidence of ZIKV infection; however, ZIKV was the predominant arbovirus circulating in 2016 in Puerto Rico. 28, 38 Conversely, false-negative laboratory results could have led to an underestimation. Furthermore, specimens were not available for 13.1% (16 of 123) of confirmed GBS cases, some of which may have been infected with ZIKV. Third, disability was assessed using self-reported information collected via telephone interview, whereas clinical assessment, including electrophysiologic studies, could have provided more accurate disability data. Fourth, apart from laboratory testing for ZIKV, DENV, and CHIKV, other etiologic triggers were not systematically identified because of constraints in public health surveillance. Additional laboratory testing was dependent on medical orders, and data collection was limited to results available in patients' medical records.
Conclusions
Despite these limitations, an island-wide surveillance in Puerto Rico allowed for comprehensive data collection to characterize GBS associated with ZIKV infection. Indicated pathophysiologic mechanisms merit continued investigation, especially to identify risk factors for developing GBS after ZIKV infection and to appropriately prepare resources to improve patients' long-term prognosis. -indicate that no specimens from GBS patients with evidence of ZIKV infection were collected during these date ranges.
